

MERRIMACK PHARMACEUTICALS INC

Form 3

May 21, 2014

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Laivins Peter N

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

05/14/2014

3. Issuer Name **and** Ticker or Trading Symbol

MERRIMACK PHARMACEUTICALS INC [MACK]

4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

SVP of Development

C/O MERRIMACK
PHARMACEUTICALS,
INC.,Â ONE KENDALL
SQUARE, SUITE B7201

(Street)

CAMBRIDGE,Â MAÂ 02139

(City)

(State)

(Zip)

6. Individual or Joint/Group
Filing(Check Applicable Line)☒ Form filed by One Reporting
Person☐ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

2,000

D

Â

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security4. Conversion
or Exercise5. Ownership
Form of6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â (1)	11/01/2021	Common Stock	40,000	\$ 6.78	D	Â
Stock Option (right to buy)	Â (2)	06/12/2022	Common Stock	10,000	\$ 6.8	D	Â
Stock Option (right to buy)	Â (3)	08/22/2022	Common Stock	22,300	\$ 7.53	D	Â
Stock Option (right to buy)	Â (4)	03/11/2023	Common Stock	35,000	\$ 6.35	D	Â
Stock Option (right to buy)	Â (5)	02/10/2024	Common Stock	100,000	\$ 5.02	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Laivins Peter N C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE, MA 02139	Â	Â	Â SVP of Development	Â

Signatures

/s/ Jeffrey A. Munsie,
attorney-in-fact

05/21/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This option vested as to 1/6th of the shares on 4/17/12 and vests in equal quarterly installments thereafter until 10/17/14.
- (2) This option vested as to 1/12th of the shares on 9/13/12 and vests in equal quarterly installments thereafter until 6/13/15.
- (3) This option vested as to 1/12th of the shares on 11/23/12 and vests in equal quarterly installments thereafter until 8/23/15.
- (4) This option vested as to 1/12th of the shares on 6/12/13 and vests in equal quarterly installments thereafter until 3/12/16.
- (5) This option vested as to 1/12th of the shares on 5/11/14 and vests in equal quarterly installments thereafter until 2/11/17.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.